Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2936 · 1 trial · 1 indication
A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.
Percentage of participants with AEs leading to discontinuation of rilvegostomig
Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC) | EXPERIMENTAL | Rilvegostomig Intravenous (IV) monotherapy |
| Dose Expansion Part B: CPI experienced NSCLC | EXPERIMENTAL | Rilvegostomig IV monotherapy |
| Dose Expansion Part C: CPI Naive NSCLC | EXPERIMENTAL | Rilvegostomig IV monotherapy |
| Dose Expansion Part D: CPI Naive NSCLC | EXPERIMENTAL | Rilvegostomig IV monotherapy |
| Dose Expansion Part E: treatment Naive Squamous NSCLC | EXPERIMENTAL | Rilvegostomig IV monotherapy |
| Name | Type | Description |
|---|---|---|
| AZD2936 | DRUG | Anti-TIGIT/Anti-PD-1 Bispecific Antibody |
Inclusion Criteria: * Written informed consent * Aged 18 or above * Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radi...
AZD2936 is an investigational small molecule being studied for the treatment of Non-Small-Cell Lung Carcinoma (NSCLC). It is currently in Phase 1 clinical development, with an active trial evaluating its use in participants with advanced or metastatic NSCLC. The drug is not yet approved and remains under clinical investigation.
AZD2936 is an anti-TIGIT/anti-PD-1 bispecific antibody, meaning it targets both TIGIT and PD-1, two immune checkpoint proteins involved in regulating T-cell responses. By binding to these targets, it is designed to modulate the immune system's ability to fight cancer cells. This mechanism is being studied in the context of Non-Small-Cell Lung Carcinoma.
AZD2936 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and efficacy of AZD2936 in patients with Non-Small-Cell Lung Carcinoma.
AZD2936 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested in clinical trials. The current Phase 1 study is active but not recruiting participants, and it is designed to assess the drug's safety, tolerability, and preliminary efficacy.
AZD2936 is being evaluated in a single active clinical trial with the identifier NCT04995523. This Phase 1 study, titled 'A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC,' has an enrollment of 212 participants and is being conducted across multiple countries, including the United States, Australia, Belgium, Brazil, China, and others.
Yes, AZD2936 is an anti-TIGIT/anti-PD-1 bispecific antibody. This means it is designed to simultaneously bind to two different targets, TIGIT and PD-1, which are immune checkpoint molecules. The drug is being studied for its potential role in treating Non-Small-Cell Lung Carcinoma by modulating immune responses.